Cell-free DNA as a biomarker in the context of cancer, viruses, and methylation

Journal of Infectious Diseases

Volumn 205, Issue 7, 2012, Pages 1032-1034

  Stebbing, Justin ^a   Bower, Mark ^a  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMMEDIATE EARLY PROTEIN BZLF1; TUMOR MARKER; VIRUS DNA; VIRUS NUCLEOPROTEIN;

BZLF1 GENE; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CELL FREE SYSTEM; CPG ISLAND; DIAGNOSTIC VALUE; DNA MARKER; DNA METHYLATION; DNA SEQUENCE; EPSTEIN BARR VIRUS INFECTION; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HUMAN; KAPOSI SARCOMA; MICROSATELLITE MARKER; NONHUMAN; NOTE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRANSACTIVATION; VIRION; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS LOAD; VIRUS PATHOGENESIS;

DNA, VIRAL; DNA-CYTOSINE METHYLASES; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION; SARCOMA, KAPOSI;

EID: 84858240544     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis023     Document Type: Note

References (21)

1. Mandel P, Metais P. Les acides nucleiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948; 142:241-3.
2. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37:646-50. (Pubitemid 8051621)
3. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987; 23: 707-12. (Pubitemid 17119706)
4. Cherepanova AV, Tamkovich SN, Bryzgunova OE, Vlassov VV, Laktionov PP. Deoxyribonuclease activity and circulating DNA concentration in blood plasma of patients with prostate tumors. Ann N Y Acad Sci 2008; 1137:218-21.
5. Zanetti-Dallenbach R, Wight E, Fan AX, et al. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res 2008; 28:921-5. (Pubitemid 351578938)
6. Chen X, Bonnefoi H, Diebold-Berger S, et al. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999; 5:2297-303. (Pubitemid 29437305)
7. Shamay et al. J Infect Dis 2012; 205:1095-9.
8. Blazar B, Patarroyo M, Klein E, Klein G. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by super-infection or sodium butyrate. J Exp Med 1980; 151:614-27. (Pubitemid 10149759)
9. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 2010; 107:850-5.
10. Kalla M, Gobel C, Hammerschmidt W. The lytic phase of Epstein-Barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J Virol 2012; 86(1):447-58.
11. Stebbing J, Bourboulia D, Johnson M, et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J Virol 2003; 77:4306-14. (Pubitemid 36350969)
12. Lagos D, Pollara G, Henderson S, et al. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat Cell Biol 2010; 12:513-19.
13. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998; 394:588-92. (Pubitemid 28366835)
14. Robey RC, Mletzko S, Bower M, et al. Ex-vivo recognition of late-lytic CD8 epitopes specific for Kaposi's sarcoma-associated herpesvirus (KSHV) by HIV/KSHV-coinfected individuals. Viral Immunol 2011; 24:211-20.
15. Robey RC, Lagos D, Gratrix F, et al. The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS One 2009; 4:e5890.
16. Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011; 29:2481-6.
17. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multi-centric Castleman disease. Blood 2011; 118:271-5.
18. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009; 113:4521-4.
19. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman's disease. Clin Exp Immunol 2008; 154:399-405.
20. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009; 20:775-9.
21. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet 2011; 12:529-41.